HEMGENIX - AN OVERVIEW

Quantity of qualified patients: CDEC mentioned the uncertainty in the amount of clients with moderately extreme to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical authorities consulted by CADTH indicated that some patients that are categorized as acquiring mild or reasonable illness could possibly have a serious